Sanofi Sponsored ADR Stock

$47.85

1.08% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US80105N1054

Symbol

SNY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Sanofi Sponsored ADR Stock price

$47.85

-3.23 6.32% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.52 1.08%

ISIN

US80105N1054

Symbol

SNY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$117.6b

Enterprise Value

$132.9b

Net debt

$15.3b

Cash

$9.4b

Shares outstanding

1.3b

Valuation (TTM | estimate)

P/E

4.92 | 4.91

P/S

1.45 | 2.19

EV/Sales

1.64 | 2.48

EV/FCF

10.38

P/B

0.69

Dividends

DPS

$2.20

Yield 1Y | 5Y

4.59% | 3.97%

Growth 1Y | 5Y

7.78% | 5.25%

Payout 1Y | 3Y

39.32% | 32.52%

Increased

2 Years

Financials (TTM | estimate)

Revenue

$80.9b | $53.7b

EBITDA

$21.8b | $16.9b

EBIT

$18.8b

Net Income

$12.0b | $12.2b

Free Cash Flow

$12.8b

Growth (TTM | estimate)

Revenue

- | 3.39%

EBITDA

- | 36.51%

EBIT

Net Income

- | 87.66%

Free Cash Flow

5.65%

Margin (TTM | estimate)

Gross

70.78%

EBITDA

26.99% | 31.42%

EBIT

23.19%

Net

14.84% | 22.79%

Free Cash Flow

15.83%

EPS

$9.73

FCF per Share

$10.22

Short interest

0.21%

Employees

82.88k

Rev per Employee

$630.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

??

29 Analysts have issued a Sanofi Sponsored ADR forecast:

22x Buy

76%

7x Hold

24%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy

76%

Hold

24%

Analyst Estimates with Stock Price Targets

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	80,929 80,929	- 100%
- Direct Costs	23,651 23,651	- 29%
Gross Profit	57,278 57,278	- 71%
- Selling and Administrative Expenses	16,510 16,510	- 20%
- Research and Development Expense	12,956 12,956	- 16%
EBITDA	21,846 21,846	- 27%
- Depreciation and Amortization	3,079 3,079	- 4%
EBIT (Operating Income) EBIT	18,767 18,767	- 23%
Net Profit	12,010 12,010	- 15%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sanofi Sponsored ADR Stock News

Neutral

PRNewsWire

●

2 days ago

Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

New fund supports nonprofit partners working to address social drivers of health and strengthen community well-being CAMBRIDGE, Mass. , June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and w...

Neutral

GlobeNewsWire

●

3 days ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy...

Neutral

Business Wire

●

8 days ago

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and ...

More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office	France
CEO	Paul Hudson
Employees	82,878
Founded	1994
Website	www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now